620 related articles for article (PubMed ID: 24659821)
21. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
[TBL] [Abstract][Full Text] [Related]
23. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.
Chen SS; Chang BY; Chang S; Tong T; Ham S; Sherry B; Burger JA; Rai KR; Chiorazzi N
Leukemia; 2016 Apr; 30(4):833-43. PubMed ID: 26582643
[TBL] [Abstract][Full Text] [Related]
24. PIM kinases as therapeutic targets against advanced melanoma.
Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
[TBL] [Abstract][Full Text] [Related]
25. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
27. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1).
Möhle R; Failenschmid C; Bautz F; Kanz L
Leukemia; 1999 Dec; 13(12):1954-9. PubMed ID: 10602415
[TBL] [Abstract][Full Text] [Related]
29. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
30. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
31. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12.
McCaig AM; Cosimo E; Leach MT; Michie AM
PLoS One; 2012; 7(11):e48929. PubMed ID: 23133664
[TBL] [Abstract][Full Text] [Related]
33. Expression and function of PIM kinases in osteosarcoma.
Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q
Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
35. Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M; Nicot C
Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
[TBL] [Abstract][Full Text] [Related]
37. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
[TBL] [Abstract][Full Text] [Related]
38. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
[TBL] [Abstract][Full Text] [Related]
39. Expression of the PIM2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia.
Kapelko-Słowik K; Dybko J; Grzymajło K; Jaźwiec B; Urbaniak-Kujda D; Słowik M; Potoczek S; Wołowiec D
Adv Clin Exp Med; 2019 Mar; 28(3):385-390. PubMed ID: 30525315
[TBL] [Abstract][Full Text] [Related]
40. Proviral integration site for Moloney murine leukemia virus (PIM) kinases promote human T helper 1 cell differentiation.
Tahvanainen J; Kyläniemi MK; Kanduri K; Gupta B; Lähteenmäki H; Kallonen T; Rajavuori A; Rasool O; Koskinen PJ; Rao KV; Lähdesmäki H; Lahesmaa R
J Biol Chem; 2013 Feb; 288(5):3048-58. PubMed ID: 23209281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
